Welcome to our dedicated page for Harrow Health SEC filings (Ticker: HROWM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
HROWM represents Harrow, Inc. 11.875% Senior Notes due 2027, listed on The Nasdaq Stock Market LLC. This SEC filings page focuses on regulatory documents that reference these senior notes and their issuer, Harrow, Inc., which operates in the pharmaceutical preparations sector. Filings such as Forms 8-K, 10-K, and 10-Q for Harrow, Inc. provide the primary source of information for understanding the context in which the HROWM notes exist.
In a reported Form 8-K, Harrow, Inc. disclosed a change in its independent registered public accounting firm. The company’s audit committee dismissed Crowe LLP and approved Deloitte & Touche LLP as the new independent registered public accounting firm, subject to completion of Deloitte’s standard client acceptance procedures and an engagement letter. The filing notes that Crowe’s report on the company’s financial statements for a referenced year did not include an adverse opinion or disclaimer of opinion and was not qualified or modified as to uncertainty, audit scope, or accounting principles. It also states that there were no disagreements or reportable events within the meaning of Item 304 of Regulation S-K during Crowe’s engagement.
Using this page for HROWM analysis
Through this page, users can review Harrow, Inc.’s SEC filings that relate to its capital structure, financial reporting, and auditor relationships, all of which are relevant when assessing the HROWM senior notes. Real-time updates from EDGAR and AI-powered summaries help explain the key points in filings such as 8-Ks, annual reports on Form 10-K, quarterly reports on Form 10-Q, and other documents that may reference the HROWM notes or the company’s broader debt and equity securities.
Harrow, Inc. Schedule 13G reports that Daniel Kaufman beneficially owns 1,878,000 shares of Common Stock, representing
The filing lists Kaufman’s sole voting and dispositive power over the 1,878,000 shares. The address and CUSIP are provided in the disclosure.
Harrow, Inc. filed a current report to furnish an updated corporate investor presentation under Regulation FD. The presentation, dated March 2026, is provided as Exhibit 99.1 and may be used by management in investor conferences and meetings.
The company specifies that this material is being furnished, not filed, so it is not subject to Section 18 liability of the Exchange Act and is only incorporated into other securities filings if expressly referenced.
Opaleye Management Inc., a 10% owner of HARROW, INC., reported open-market sales of Harrow common stock through affiliated entities on March 3 and 4, 2026.
Opaleye, L.P. sold 59,000 and 134,000 shares at weighted average prices of
HARROW, INC. insider Opaleye Management Inc., as portfolio manager of a separately managed account, reported an open-market sale of 5,000 shares of common stock on February 27, 2026 at a price of $54.18 per share.
After this sale, the managed account held 65,000 shares indirectly attributed to Opaleye. A separate holding of 3,815,000 shares is owned directly by Opaleye, L.P., for which Opaleye Management Inc. is the investment manager. Opaleye Management Inc. disclaims beneficial ownership of the reported shares except to the extent of its pecuniary interest.
Harrow, Inc. outlines its position as a North American leader in ophthalmic disease management, combining branded pharmaceuticals with its ImprimisRx compounding business. The company markets numerous FDA-approved eye products and is building a late-stage pipeline, highlighted by MELT-300 for non‑IV, non‑opioid sublingual procedural sedation.
MELT-300 has completed Phase 3 under a Special Protocol Assessment, with an NDA planned for the first half of 2027 and a targeted U.S. launch in the second half of 2028. Harrow also plans mid‑2026 and mid‑2027 launches for BYOOVIZ and OPUVIZ biosimilars and BYQLOVI for post‑operative inflammation.
In November 2025, Harrow acquired the remaining equity of Melt Pharmaceuticals for an initial $4.3 million cash payment plus potential milestone-based cash and equity tied to MELT‑300 approval, reimbursement, and sales. Research and development expenses rose to $20.94 million in 2025 from $12.23 million in 2024 and $6.652 million in 2023, reflecting increased investment in pipeline assets and the Melt acquisition.
The company reports two segments—Branded and ImprimisRx—both U.S.-based, and had 373 employees as of February 25, 2026. Harrow emphasizes regulatory and reimbursement complexity, competition from larger pharmaceutical and biosimilar players, and evolving federal and state pharmacy rules, especially around its 503A/503B compounding facilities, as key risks to growth and profitability.
Harrow, Inc. reported strong growth for Q4 and full-year 2025 and issued 2026 guidance. Quarterly revenue reached $89.1 million, up 33% from $66.8 million, while full-year revenue rose 36% to $272.3 million from $199.6 million. Q4 GAAP net income was $6.6 million, though the company posted a $5.1 million net loss for 2025. Adjusted EBITDA grew to $24.2 million in Q4 and $61.9 million for the year. Operating cash flow swung to a positive $43.9 million in 2025 from $(22.2) million in 2024, and cash and cash equivalents were $72.9 million at year-end. Management highlighted strong momentum in key ophthalmic brands VEVYE, IHEEZO and TRIESENCE and outlined plans to expand sales teams and invest in growth initiatives. For 2026, Harrow guides to $350–$365 million in revenue and $80–$100 million in Adjusted EBITDA, with results expected to be more heavily weighted to the second half of the year.
Harrow, Inc.’s chief commercial officer, Patrick William Sullivan, received two new restricted stock unit awards. On 01/30/2026 he was granted 25,000 RSUs and 15,000 RSUs under the company’s 2025 Incentive and Awards Plan, each RSU representing one share of Harrow common stock upon vesting.
The 25,000 RSUs have a five-year term and vest only if Harrow’s revenue reaches
Harrow, Inc. filed a Form 3 for Chief Commercial Officer Patrick William Sullivan, reporting a stock option over 30,000 shares of common stock. The option has an exercise price of $39 per share and expires on September 1, 2035.
According to the vesting schedule, 25% of the option shares vest on the one-year anniversary of the grant date. The remaining shares vest in 12 equal quarterly installments over the following three years, becoming fully vested and exercisable on September 1, 2029. The option is held directly.
Harrow, Inc. filed an update covering its outlook and leadership team. The company reaffirmed its full-year 2025 revenue guidance in a range of $270 million to $280 million, signaling no change to its previously communicated expectations.
Harrow also appointed Patrick W. Sullivan as Chief Commercial Officer, effective January 30, 2026. He brings more than 25 years of commercial leadership experience from roles at Corium Therapeutics, AstraZeneca, Shire, Adolor, Novartis, and Bayer. Under his offer letter, Sullivan will receive a $425,000 annual base salary, a target annual bonus equal to 40% of base compensation, and 40,000 restricted stock units. Of these, 25,000 RSUs vest if Harrow’s revenue reaches $230,000,000 in a calendar quarterly period, and 15,000 RSUs vest three years from the award date.
Harrow, Inc. notified that its Audit Committee dismissed Crowe LLP as the company's independent registered public accounting firm, effective immediately, and engaged Deloitte to serve as the new independent registered public accounting firm to audit the consolidated financial statements for the year ending December 31, 2025. The engagement with Deloitte was communicated on September 17, 2025 and is subject to Deloitte's standard client acceptance procedures and execution of an engagement letter. The filing references a letter from Crowe LLP dated September 19, 2025, and an Inline XBRL cover page file as exhibits. The disclosure does not state the reasons for the change or provide audit opinions or financial impacts.